Abdullah Khan

Abdullah Khan's research focuses on treatments for relapsed/refractory multiple myeloma, a type of blood cancer, with particular attention to newer immune-based therapies such as CAR T-cell therapy (a treatment using engineered immune cells) and bispecific antibodies like teclistamab and talquetamab. Much of the work involves real-world studies comparing these therapies to standard treatments and examining outcomes in specific patient groups, including those with kidney impairment or from underrepresented racial groups. The research also includes work on stem cell transplantation access and clinical trial landscape analysis in myeloma.

Publication output has grown substantially over the last decade, rising from single digits in 2017-2019 to over 30 publications in 2025, indicating an increasingly active and productive research program.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026